Latest News by Industry
STAMFORD, Conn. (AP) _ Cara Therapeutics Inc. (CARA) on Monday reported a loss of $23.2 million in its third quarter.
On a per-share basis, the Stamford, Connecticut-based company said it had a loss of 43 cents.
The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of 42 cents per share.
The biotechnology company posted revenue of $10.8 million in the period, topping Street forecasts. Five analysts surveyed by Zacks expected $8.4 million.
Cara shares have decreased 23% since the beginning of the year. In the final minutes of trading on Monday, shares hit $9.34, a decrease of 48% in the last 12 months.
_____
This story was generated by Automated Insights (http://automatedinsights.com/ap) using data from Zacks Investment Research. Access a CARA">Zacks stock report on CARA at https://www.zacks.com/ap/CARA